Literature DB >> 25556062

Modified Si-Miao-San inhibits inflammation and promotes glucose disposal in adipocytes through regulation of AMP-kinase.

Jiang-Lin Yang1, Jun-Lian Wang1, Fang Huang1, Kang Liu1, Bao-Lin Liu2.   

Abstract

Modified Si-Miao-San (mSMS) is composed of Rhizoma Coptidis, Cortex Phellodendri, Rhizoma Coptidis Semen Coicis and Atractylodes Rhizome. The prescription is used for the management of diabetes and insulin resistance in the clinic. This study aims to investigate its regulation of glucose disposal in adipocytes. Differentiated 3T3-L1 adipocytes were stimulated with conditioned medium derived from activated macrophages to induce insulin resistance and observed the effects of Mac-CM on insulin-mediated glucose uptake along the insulin receptor substrate-1/PI3K/Akt signaling pathway. Moreover, its regulation of AMPK phosphorylation was also investigated. mSMS enhanced AMPK phosphorylation and promoted basal glucose uptake in adipocytes; mSMS inhibited NF-κB activation by reducing P65 phosphorylation and improved insulin-stimulated IRS-1 tyrosine and Akt phosphorylation, leading to the restoration of insulin-mediated glucose uptake when cells were exposed to inflammatory stimulation. These beneficial effects were diminished in the presence of the AMPK inhibitor compound C. mSMS positively regulated AMPK activity, and this action contributed to improving insulin PI3K signaling by the beneficial regulation of IRS-1 function through inhibition of inflammation in adipocytes.
Copyright © 2014 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMP-kinase; Adipocytes; Inflammation; Insulin resistance; Modified Si-Miao-San

Mesh:

Substances:

Year:  2014        PMID: 25556062     DOI: 10.1016/S1875-5364(14)60134-5

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN: 1875-5364


  1 in total

Review 1.  Modified Si-Miao Pill for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.

Authors:  Hui Wang; Yao Huang; Pan Shen; Yu Wang; Kai Qin; Ying Huang; Xin Ba; Weiji Lin; Zhe Chen; Shenghao Tu
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-21       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.